Delivery Order SPE2DB24D1201-SPE2DB25FJDXH
- Not listed
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injections, with a ceiling value of $20,906.28 under a firm fixed-price contract. This non-set-aside delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply framework with DLA and is scheduled for completion by August 12, 2025. The pharmaceutical will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a delivery order valued at $36,944.08 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, competitively awarded delivery order represents a direct fulfillment under the company's existing pharmaceutical supply agreement with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $12,307.65. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This...
- The Defense Logistics Agency awarded a $4,028.61 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of August 14, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injections, with a contract ceiling value of $1,709.46. This is a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDXHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $7,947.84. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. As a prime contractor under the DLA's comprehensive pharmaceutical supply vehicle, the company supplies a broad spectrum of pharmaceutical products and medical supplies to support Defense Health Agency operations and other federal healthcare systems. The Dupixent delivery under this order contributes to the company's extensive portfolio of specialty medications and biologics distributed through the DLA's global pharmaceutical support network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 8/14/25 |